Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units

European Respiratory Journal

Volumn 24, Issue 1, 2004, Pages 101-106

  O'Carroll, M R ^a   Syrmis, M W ^b   Wainwright, C E ^b   Greer, R M ^b   Mitchell, P ^b   Coulter, C ^c   Sloots, T P ^b   Nissen, M D ^b,c   Bell, Scott C ^a,b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QUEENSLAND HEALTH   (Australia)

Author keywords

Clonal strain; Cystic fibrosis; Pseudomonas aeruginosa; Pulsed field gel electrophoresis

Indexed keywords

AMIKACIN; AZTREONAM; BACITRACIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTHROPOMETRY; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERIUM ISOLATE; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GENOTYPE; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MALE; MICROBIAL MORPHOLOGY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SPIROMETRY; SPUTUM CULTURE; STRAIN IDENTIFICATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTI-BACTERIAL AGENTS; AUSTRALIA; CHILD; CONFIDENCE INTERVALS; CROSS INFECTION; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; HOSPITAL UNITS; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK ASSESSMENT; SEX DISTRIBUTION; SPUTUM; STATISTICS, NONPARAMETRIC;

EID: 3543088101     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00122903     Document Type: Article

References (33)

1. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60: 539-574.
2. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 38: 699-704.
3. Govan JR. Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex. J R Soc Med 2000; 93: Suppl. 38, 40-45.
4. Spencker FB, Haupt S, Claros MC, et al. Epidemiologic characterization of Pseudomonas aeruginosa in patients with cystic fibrosis. Clin Microbiol Infect 2000; 6: 600-607.
5. Romling U, Fiedler B, Bobhammer J, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis 1994; 170: 1616-1621.
6. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996; 34: 1129-1135.
7. Grothues D, Koopmann U, von der Hardt H, Tummler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol 1988; 26: 1973-1977.
8. Tummler B, Koopmann U, Grothues D, Weissbrodt H, Steinkamp G, von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol 1991; 29: 1265-1267.
9. Wolz C, Kiosz G, Ogle JW, et al. Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis: use of a DNA probe. Epidemiol Infect 1989; 102: 205 214.
10. Anthony M, Rose B, Pegler MB, et al. Genetic analysis of Pseudomonas aeruginosa isolates from the sputa of Australian adult cystic fibrosis patients. J Clin Microbiol 2002; 40: 2772-2778.
11. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002; 166: 983-987.
12. Cheng K, Smyth RL, Govan JR, et al. Spread of betalactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996; 348: 639-642.
13. Jones AM, Govan JR, Doherty CJ, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001; 358: 557-558.
14. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986; 17: 505-516.
15. Jones AM, Dodd ME, Doherty CJ, Govan JR, Webb AK. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002; 57: 924-925.
16. Speert DP, Campbell ME, Henry DA, et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med 2002; 166: 988-993.
17. Pitt TL. Cross infection of cystic fibrosis patients with Pseudomonas aeruginosa. Thorax 2002; 57: 921.
18. Ramsey BW. To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa? Am J Respir Crit Care Med 2002; 166: 906-907.
19. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cystic Fibrosis 2003; 2: 29-34.
20. De Vos D, Lim A Jr, Pirnay JP, et al. Direct detection and identification of Pseudomonas aeruginosa in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane lipoprotein genes, oprI and oprL. J Clin Microbiol 1997; 35: 1295-1299.
21. Pirnay JP, De Vos D, Duinslaeger L, et al. Quantitation of Pseudomonas aeruginosa in wound biopsy samples: from bacterial culture to rapid real-time polymerase chain reaction. Crit Care 2000; 4: 255-261.
22. The National Committee for Clinical Laboratory Standards. Twelfth International Supplement M100-S12 Vol. 22 No. 1: Performance standards for antimicrobial susceptibility testing. Wayne, PA, USA, 2002.
23. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39: 183-190.
24. Cystic fibrosis consensus conference. Microbiology and infectious disease in cystic fibrosis. Bethesda, MD, Cystic Fibrosis Foundation, 1994; Vol. 5, Section 1, pp. 1-26.
25. Tenover FC, Arbeit RD, Goering RV. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Molecular typing working group of the Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol 1997; 18: 426-39.
26. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically infected by P. aeruginosa. Lancet 2001; 358: 558-560.
27. Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003; 58: 794-796.
28. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Resp J 2002; 20: 658-664.
29. Govan JRW. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J Cystic Fibrosis 2002; 1: Suppl. 2, S203-S208.
30. Denton M, Kerr K, Mooney L, et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a paediatric cystic fibrosis center. Pediatr Pulmonol 2002; 34: 257-261.
31. Jones AM, Govan JR, Doherty CJ, et al. Identification of airborne dissemination of epidemic multi-resistant strains of Pseudomonas aeruginosa at a CF centre during a cross-infection outbreak. Thorax 2003; 58: 525-527.
32. Saiman L, Siegel J, for the Cystic Fibrosis Foundation. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practises to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003; 24: Suppl. 5, S1-S52.
33. The CF Trust's Control of Infection Group. Pseudomonas aeruginosa infection in people with cystic fibrosis. Kent, UK, Cystic Fibrosis Trust, 2001; pp. 1-18.